{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=13", "query": { "condition": "DLBCL", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 325, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=DLBCL&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T04:24:03.204Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00776802", "title": "GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "GCS-100", "type": "DRUG" }, { "name": "Etoposide; Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "La Jolla Pharmaceutical Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-07", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776802" }, { "nct_id": "NCT02252146", "title": "Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "IMO-8400", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idera Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2014-06", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 12, "location_summary": "Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02252146" }, { "nct_id": "NCT05753501", "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Cancer" ], "interventions": [ { "name": "ABBV-101", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2023-06-09", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 14, "location_summary": "Tucson, Arizona • Orange, California • Palo Alto, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05753501" }, { "nct_id": "NCT05512390", "title": "A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma" ], "interventions": [ { "name": "ABBV-319", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2023-04-26", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 8, "location_summary": "Tucson, Arizona • Miami, Florida • Minneapolis, Minnesota + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05512390" }, { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" }, { "nct_id": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "Mantle Cell Lymphoma (MCL)", "Richter's Syndrome", "T-cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "Marginal Zone Lymphoma", "Myeloid Malignancies", "Acute Myeloid Leukemia (AML)", "Chronic Myelomonocytic Leukemia (CMML)", "Myelodysplastic Syndrome (MDS)", "MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome" ], "interventions": [ { "name": "PRT2527", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2023-09-12", "completion_date": "2026-01-21", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 5, "location_summary": "Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05665530" }, { "nct_id": "NCT04806035", "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL", "SLL", "Richter's Transformation", "Indolent Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma", "Aggressive Lymphoma", "DLBCL", "Mediastinal Large B-cell Lymphoma", "MCL" ], "interventions": [ { "name": "TG-1801", "type": "BIOLOGICAL" }, { "name": "Ublituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-04-28", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 5, "location_summary": "Fayetteville, Arkansas • Hackensack, New Jersey • Chattanooga, Tennessee + 2 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04806035" }, { "nct_id": "NCT02914938", "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Follicular Lymphoma (FL)", "Marginal Zone B Cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "High Grade Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma (MCL)" ], "interventions": [ { "name": "ME-401", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MEI Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2016-10", "completion_date": "2023-03-29", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 23, "location_summary": "Tucson, Arizona • Corona, California • Miami, Florida + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02914938" }, { "nct_id": "NCT04601831", "title": "'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Focal radiation therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-12-23", "completion_date": "2025-05-27", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04601831" }, { "nct_id": "NCT01479842", "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "BTK inhibitor PCI-32765", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Kami Maddocks, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03-26", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-23T04:24:03.204Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479842" } ] }